Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASCT-I in advanced solid tumors
NCT02858232Phase 2Unknown
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Aug 2016
- Primary completion
- Oct 2018
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, TCR-Engineered T Cells
01
Overview
Phase 2, open-label, single-arm trial of MASCT-1 in solid tumor, sponsored by First People's Hospital of Lianyungang City. Primary endpoint: Incidence of treatment-related adverse events at 2 years. Status: unknown.
02
Drugs
MASCT-1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02858232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858232.